T Cell Lymphoma Clinical Trial
Official title:
Phase II Study of Mogamulizumab With DA-EPOCH in Patients With Aggressive T Cell Lymphoma
Single- arm Phase II study evaluating the combination of mogamulizumab (MOGA) added on top of standard of care dose adjusted EPOCH (DA-EPOCH) in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T cell lymphoma including patients with Adult T-cell leukemia/lymphoma (ATLL).
This is a single arm, open label, multicenter phase 2 study of DA-EPOCH and Mogamulizumab in patients with newly diagnosed or relapsed/refractory (for CTCL only) aggressive T-cell lymphomas including ATLL and transformed Mycosis Fungoides/Sézary syndrome (MF/SS). The hypothesis is that this combination is effective and will produce a CR rate of 80%. DA-EPOCH and Mogamulizumab will be administered for 6 cycles and depending on the histology, consolidative strategies including SCT will be considered. Response assessments will occur at pre-specified intervals. Dose adjustments for specific toxicities with drugs are detailed in the protocol. Based on statistical analysis, a maximum of 36 patients will need to be accrued to evaluate for disease response based on historical control. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04653649 -
CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06420076 -
Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells
|
Phase 1/Phase 2 | |
| Completed |
NCT01561833 -
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients
|
Phase 1 | |
| Withdrawn |
NCT04334174 -
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas
|
Phase 2 | |
| Recruiting |
NCT05367856 -
Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00798096 -
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03770000 -
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01430013 -
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT04502446 -
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
|
Phase 1 | |
| Terminated |
NCT04973527 -
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor
|
Phase 1 | |
| Recruiting |
NCT05230680 -
Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03672084 -
Allo-HSCT as First-line Consolidation in High-risk PTCL
|
||
| Recruiting |
NCT05852028 -
A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma
|
||
| Enrolling by invitation |
NCT03628612 -
Long-term Follow-up of Patients Treated With Autologous T Cells Genetically Modified
|
Phase 2 | |
| Recruiting |
NCT00974324 -
Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma
|
Phase 2 | |
| Completed |
NCT00877656 -
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT05772728 -
Chidamide Combined With Azacitidine and Mitoxantrone Liposome in the Treatment of Relapsed/Refractory (nTFHL)
|
N/A | |
| Completed |
NCT01300026 -
AMG 319 Lymphoid Malignancy FIH
|
Phase 1 | |
| Terminated |
NCT00880867 -
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04840875 -
Phase I Clinical Trial of Autologous CD7-CAR T Cells in the Treatment of High-risk Acute T-cell Leukemia / Lymphoma
|
Phase 1 |